 |
 |
|
|
|
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
||||
 |
 |
 |
 |
 |
 |
||||
 | |||||
|
EUnetHTA is pleased to announce that as of June 29, 2012, the first batch of draft methodology guidelines on choice of comparator, composite endpoints, surrogate endpoints and applicability for Relative Effectiveness Assessment of Pharmaceuticals has entered the public consultation phase.
This consultation will take place between 29 June and 10 September 2012.
Consultation documents :
• Guideline on criteria for the choice of the most appropriate • Guideline on composite endpoints • Guideline on surrogate endpoints • Guideline on applicability of evidence • Public Consultation Comments Form
 |
Enjeux Opérationnels du "Parcours de Soins". L’évaluation médico-économique. L’exemple de l’AVC.
